Comprehensive Analysis Identifies the PPAR-Targeted Genes Associated with Ovarian Cancer Prognosis and Tumor Microenvironment.

IF 3.5 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
PPAR Research Pub Date : 2023-01-01 DOI:10.1155/2023/6637414
Xiao-Fei Leng, Gao-Fa Wang, Hao Yin, Feng Wei, Kang-Kang Zeng, Yi-Qun Zhang
{"title":"Comprehensive Analysis Identifies the PPAR-Targeted Genes Associated with Ovarian Cancer Prognosis and Tumor Microenvironment.","authors":"Xiao-Fei Leng,&nbsp;Gao-Fa Wang,&nbsp;Hao Yin,&nbsp;Feng Wei,&nbsp;Kang-Kang Zeng,&nbsp;Yi-Qun Zhang","doi":"10.1155/2023/6637414","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is a significant role for peroxisome proliferator-activated receptors (PPARs) in the development of cancer. Nevertheless, the role of PPARs-related genes in ovarian cancer (OC) remains unclear.</p><p><strong>Methods: </strong>The open-accessed data used for analysis were downloaded from The Cancer Genome Atlas database, which was analyzed using the R software.</p><p><strong>Results: </strong>In our study, we comprehensively investigated the PPAR target genes in OC, including their biological role. Meanwhile, a prognosis signature consisting of eight PPAR target genes was established, including apolipoprotein A-V, UDP glucuronosyltransferase 2 family, polypeptide B4, TSC22 domain family, member 1, growth hormone inducible transmembrane protein, renin, dedicator of cytokinesis 4, enoyl CoA hydratase 1, peroxisomal (ECH1), and angiopoietin-like 4, which showed a good prediction efficiency. A nomogram was constructed by combining the clinical feature and risk score. Immune infiltration and biological enrichment analysis were applied to investigate the difference between high- and low-risk patients. Immunotherapy analysis indicated that low-risk patients might respond better to immunotherapy. Drug sensitivity analysis indicated that high-risk patients might respond better to bleomycin, nilotinib, pazopanib, pyrimethamine, and vinorelbine, yet worse to cisplatin and gefitinib. Furthermore, the gene ECH1 was selected for further analysis.</p><p><strong>Conclusions: </strong>Our study identified a prognosis signature that could effectively indicates patients survival. Meanwhile, our study can provide the direction for future studies focused on the PPARs in OC.</p>","PeriodicalId":20439,"journal":{"name":"PPAR Research","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195182/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PPAR Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/6637414","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There is a significant role for peroxisome proliferator-activated receptors (PPARs) in the development of cancer. Nevertheless, the role of PPARs-related genes in ovarian cancer (OC) remains unclear.

Methods: The open-accessed data used for analysis were downloaded from The Cancer Genome Atlas database, which was analyzed using the R software.

Results: In our study, we comprehensively investigated the PPAR target genes in OC, including their biological role. Meanwhile, a prognosis signature consisting of eight PPAR target genes was established, including apolipoprotein A-V, UDP glucuronosyltransferase 2 family, polypeptide B4, TSC22 domain family, member 1, growth hormone inducible transmembrane protein, renin, dedicator of cytokinesis 4, enoyl CoA hydratase 1, peroxisomal (ECH1), and angiopoietin-like 4, which showed a good prediction efficiency. A nomogram was constructed by combining the clinical feature and risk score. Immune infiltration and biological enrichment analysis were applied to investigate the difference between high- and low-risk patients. Immunotherapy analysis indicated that low-risk patients might respond better to immunotherapy. Drug sensitivity analysis indicated that high-risk patients might respond better to bleomycin, nilotinib, pazopanib, pyrimethamine, and vinorelbine, yet worse to cisplatin and gefitinib. Furthermore, the gene ECH1 was selected for further analysis.

Conclusions: Our study identified a prognosis signature that could effectively indicates patients survival. Meanwhile, our study can provide the direction for future studies focused on the PPARs in OC.

Abstract Image

Abstract Image

Abstract Image

综合分析确定ppar靶向基因与卵巢癌预后和肿瘤微环境相关。
背景:过氧化物酶体增殖物激活受体(PPARs)在癌症的发生发展中起着重要作用。然而,ppars相关基因在卵巢癌(OC)中的作用尚不清楚。方法:从The Cancer Genome Atlas数据库中下载开放获取的分析数据,使用R软件进行分析。结果:在我们的研究中,我们全面研究了PPAR靶基因在OC中的作用,包括它们的生物学作用。同时,建立了由载脂蛋白a - v、UDP糖醛酸糖基转移酶2家族、多肽B4、TSC22结构域家族、成员1、生长激素诱导跨膜蛋白、肾素、细胞分裂专一者4、烯酰辅酶a水合酶1、过氧化物酶体(ECH1)、血管生成素样4等8个PPAR靶基因组成的预后标记,显示出较好的预测效果。结合临床特征和风险评分构建nomogram。应用免疫浸润和生物富集分析探讨高、低危患者的差异。免疫治疗分析表明,低危患者可能对免疫治疗反应更好。药物敏感性分析显示,高危患者对博来霉素、尼罗替尼、帕唑帕尼、乙胺嘧啶和长春瑞滨的反应较好,而对顺铂和吉非替尼的反应较差。进一步选择ECH1基因进行分析。结论:我们的研究确定了一个预后标志,可以有效地指示患者的生存。同时,我们的研究也可以为今后关注OC中ppar的研究提供方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
PPAR Research
PPAR Research MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
6.20
自引率
3.40%
发文量
17
审稿时长
12 months
期刊介绍: PPAR Research is a peer-reviewed, Open Access journal that publishes original research and review articles on advances in basic research focusing on mechanisms involved in the activation of peroxisome proliferator-activated receptors (PPARs), as well as their role in the regulation of cellular differentiation, development, energy homeostasis and metabolic function. The journal also welcomes preclinical and clinical trials of drugs that can modulate PPAR activity, with a view to treating chronic diseases and disorders such as dyslipidemia, diabetes, adipocyte differentiation, inflammation, cancer, lung diseases, neurodegenerative disorders, and obesity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信